Soleil Boughton Sells 268,932 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 268,932 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $27.75, for a total transaction of $7,462,863.00. Following the sale, the insider now owns 169,803 shares of the company’s stock, valued at approximately $4,712,033.25. This represents a 61.30 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Soleil Boughton also recently made the following trade(s):

• On Tuesday, November 26th, Soleil Boughton sold 2,343 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.90, for a total transaction of $70,055.70.
• On Tuesday, October 29th, Soleil Boughton sold 2,339 shares of Hims & Hers Health stock. The stock was sold at an average price of $23.16, for a total value of $54,171.24.
• On Tuesday, October 15th, Soleil Boughton sold 2,339 shares of Hims & Hers Health stock. The shares were sold at an average price of $20.41, for a total value of $47,738.99.

Hims & Hers Health Stock Down 7.0 %

Shares of HIMS stock opened at $25.74 on Thursday. The stock has a market cap of $5.62 billion, a P/E ratio of 58.50 and a beta of 1.31. Hims & Hers Health, Inc. has a fifty-two week low of $8.14 and a fifty-two week high of $35.02. The business has a fifty day simple moving average of $26.97 and a 200-day simple moving average of $21.59.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. The company had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm’s quarterly revenue was up 77.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.04) earnings per share. On average, sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analyst Ratings Changes

HIMS has been the topic of a number of recent research reports. BTIG Research began coverage on Hims & Hers Health in a report on Tuesday. They issued a “buy” rating and a $35.00 target price on the stock. Morgan Stanley began coverage on shares of Hims & Hers Health in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $42.00 price objective on the stock. Deutsche Bank Aktiengesellschaft raised their target price on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th. Needham & Company LLC boosted their price target on shares of Hims & Hers Health from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Monday. Finally, Canaccord Genuity Group raised their price objective on shares of Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research report on Monday, December 2nd. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $24.80.

Institutional Investors Weigh In On Hims & Hers Health

A number of institutional investors and hedge funds have recently bought and sold shares of HIMS. GAMMA Investing LLC raised its holdings in shares of Hims & Hers Health by 2,173.7% in the fourth quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock worth $54,000 after acquiring an additional 2,152 shares during the last quarter. Quest Partners LLC increased its position in Hims & Hers Health by 5,944.1% during the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after purchasing an additional 3,507 shares in the last quarter. Van ECK Associates Corp acquired a new position in Hims & Hers Health in the 2nd quarter valued at about $111,000. CWM LLC lifted its holdings in Hims & Hers Health by 21.4% in the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after purchasing an additional 1,054 shares in the last quarter. Finally, Quarry LP boosted its stake in shares of Hims & Hers Health by 91.0% during the 3rd quarter. Quarry LP now owns 6,113 shares of the company’s stock worth $113,000 after purchasing an additional 2,913 shares during the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.